p53-Oriented cancer therapies: Current progress
Open Access
- 1 February 1999
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 10 (2) , 139-150
- https://doi.org/10.1023/a:1008368500557
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- Tumor Eradication by Wild-type p53-specific Cytotoxic T LymphocytesThe Journal of Experimental Medicine, 1997
- Heat shock induces transient p53-dependent cell cycle arrest at G1/SOncogene, 1997
- The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapyImmunology Today, 1996
- CLINICAL IMPLICATIONS OF THE p53 GENEAnnual Review of Medicine, 1996
- Mutant Oncopeptide Immunization Induces CTL Specifically Lysing Tumor Cells Endogenously Expressing the Corresponding Intact Mutant p53Hybridoma, 1995
- The dominating effect of mutant p53Nature Genetics, 1995
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994
- Stable Expression of the Wild-Typep53Gene in Human Lung Cancer Cells after Retrovirus-Mediated Gene TransferHuman Gene Therapy, 1993
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature, 1993
- p53 is required for radiation-induced apoptosis in mouse thymocytesNature, 1993